London-based Verdiva Bio launches with 398.4M to challenge Ozempic's reign in obesity treatment - Silicon CanalsVerdiva Bio launches with $411M funding to develop innovative therapies for obesity and cardiometabolic disorders.Leading therapy, VRB-101, shows strong efficacy in initial trials.
With M&A Deal, Click Therapeutics' Digital Prospects in Metabolic Disease Get Better - MedCity NewsClick Therapeutics acquired Better Therapeutics to broaden its reach in cardiometabolic disorders, leveraging Better's FDA-authorized type 2 diabetes mobile app for personalized treatment plans.